Skip to main content
. 2019 May 7;39(5):BSR20181374. doi: 10.1042/BSR20181374

Figure 3. miR-20a-5p targets RRM2 to reverse gemcitabine resistance.

Figure 3

(A) qRT-PCR of MIA-PaCa2-GEM cells lipofected with miR-20a-5p mimic. (B) Western blot analysis of MIAPaCa2-GEM cells lipofected with miR-20a-5p mimic. (C) Time–response kinetics evaluated by MTT assay in MIA-PaCa2-GEM cells after lipotransfection with miR-20a-5p mimic or control in the presence of gemcitabine. (D) Apoptosis analysis in MIA-PaCa2-GEM cells staining with FITC-conjugated Annexin V/PI after lipotransfection with miR-20a-5p mimic or control in the presence of gemcitabine for 72 h; Western blot analysis of caspase-3 in MIAPaCa2-GEM cells. (E) Time–response kinetics evaluated by MTT assay in MIA-PaCa2-GEM cells after lipotransfection with miR-20a-5p inhibitor or control in the presence of gemcitabine. (F) Apoptosis analysis in MIA-PaCa2-GEM cells staining with FITC-conjugated Annexin V/PI after lipotransfection with miR-20a-5p inhibitor or control in the presence of gemcitabine for 72 h; Western blot analysis of caspase-3 in MIAPaCa2-GEM cells. Each experiment was performed three times; **P<0.01.